Brogden r n (25 resultados)

Condición: New.

Condición: As New. Unread book in perfect condition.

Condición: As New. Unread book in perfect condition.

Paperback. Condición: New. Softcover reprint of the original 1st ed. 1979.

Paperback or Softback. Condición: New. Antihypertensive Drugs Today. Book.

Condición: New.

Condición: New.

Paperback. Condición: New.

Condición: New.

Condición: New.

Condición: New. In English.

Condición: As New. Unread book in perfect condition.

Condición: As New. Unread book in perfect condition.

Condición: New. pp. 200.

Paperback. Condición: Brand New. 200 pages. 9.25x6.10x0.46 inches. In Stock.

Condición: NEW.

Condición: New. of Volume 4.- I Antihypertensive Drugs: Clinical Pharmacology and Therapeutic Use.- 1. Diuretics.- 1.1 Mechanism of Action.- 1.2 Pharmacokinetics.- 1.3 Clinical Use.- 1.4 Side Effects.- 2. Sympathetic Inhibiting Agents.- 2.1 Ganglion Blocking Agents.- 2.2 G.

Paperback. Condición: New. Softcover reprint of the original 1st ed. 1979.

Condición: new. Questo è un articolo print on demand.

Paperback. Condición: Brand New. 200 pages. 9.25x6.10x0.46 inches. In Stock. This item is printed on demand.

Condición: New. Print on Demand pp. 200 Illus.

Condición: New. PRINT ON DEMAND pp. 200.

Taschenbuch. Condición: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Inhaltsangabeof Volume 4.- I Antihypertensive Drugs: Clinical Pharmacology and Therapeutic Use.- 1. Diuretics.- 1.1 Mechanism of Action.- 1.2 Pharmacokinetics.- 1.3 Clinical Use.- 1.4 Side Effects.- 2. Sympathetic Inhibiting Agents.- 2.1 Ganglion Blocking Agents.- 2.2 Guanethidine and Other Adrenergic Neurone Blocking Drugs.- 2.3 Rauwolfia Alkaloids.- 2.4 Methyldopa.- 2.5 Clonidine.- 2.6 Prazosin.- 2.7 -Adrenoceptor Blocking Agents.- 2.8 Labetalol.- 2.9 MAO Inhibitors.- 3. Direct-acting Vasodilators.- 3.1 Hydrallazine.- 3.2 Minoxidil.- 3.3 Diazoxide.- 3.4 Sodium Nitroprusside.- 4. Angiotensin II Analogues and Converting Enzyme Inhibitors.- 5. Treatment Regimens.- 5.1 Mild Hypertension.- 5.2 Moderate to Severe Hypertension.- 5.3 Resistant Hypertension.- 5.4 Hypertensive Emergencies and Presence of Complications.- II Metoprolol: A Review of its Pharmacological Properties and Therapeutic Efficacy in Hypertension.- 1. Animal Pharmacodynamic Studies.- 1.1 -Adrenoceptor Blocking Effect.- 1.2 Partial Agonist Activity.- 1.3 -Adrenoceptor Selectivity.- 1.4 Antihypertensive Effect.- 1.5 Cardiovascular Haemodynamics in Dogs.- 1.6 Toxicology Studies.- 1.7 Dysmotphology and Reproduction Studies.- 2. Animal Pharmacokinetic Studies.- 2.1 Absorption.- 2.2 Half-Life.- 2.3 Distribution.- 2.4 Metabolism.- 3. Human Pharmacodynamic Studies.- 3.1 Effect on Heart Rate and Cardiac Output.- 3.2 Effect on Blood Pressure.- 3.3 -Adrenoceptor Selectivity.- 3.4 Effect on Plasma Renin Activity.- 3.5 Metabolic Effects.- 4. Pharmacokinetic Studies in Man.- 4.1 Absorption.- 4.2 Distribution.- 4.3 Metabolism and Excretion.- 4.4 Plasma Concentration and Clinical Effects.- 5. Therapeutic Trials.- 5.1 Comparison with Placebo.- 5.2 Comparison with Other Drugs.- 5.3 Metoprolol Combined with Other Drugs.- 5.4 Long-term Treatment of Hypertension.- 5.5 Is the Efficacy of Metoprolol in Hypertension Influenced by Frequency of Administration .- 5.6 What is the Role of Metoprolol in Hypertension .- 6. Side Effects.- 7. Contraindications.- 8. Precautions.- 9. Dosage.- 10. Overdosage.- III Labetalol: A Review of its Pharmacology and Therapeutic Use in Hypertension.- 1. Pharmacology.- 1.1 Blockade of - and -Adrenoceptors.- 1.2 Haemodynamic Effects.- 1.3 Effect on Plasma Renin Activity and Plasma Angiotensin II.- 1.4 Effect on Respiratory Function.- 1.5 Animal Toxicological Studies.- 1.6 Mode of Action.- 2. Pharmacokinetics.- 2.1 Absorption.- 2.2 Distribution.- 2.3 Elimination.- 2.4 Plasma Concentration and Clinical Effects.- 2.5 Influence of Disease on Kinetics.- 3. Therapeutic Trials.- 3.1 Open Studies.- 3.2 Placebo-Controlled Trials.- 3.3 Labetalol Compared with a -Adrenoceptor Blocker Alone or in Combination with an -Adrenoceptor Blocker.- 3.4 Use in Phaeochromocytoma.- 3.5 Intravenous Labetalol in Severe Hypertension.- 3.6 Labetalol in Clonidine Withdrawal Hypertension.- 4. What is the Role of Labetalol in Hypertension .- 5. Side Effects.- 6. Precautions.- 7. Dosage.- 7.1 Initial Dosage, Oral.- 7.2 Dosage Adjustment.- 7.3 Intravenous Labetalol.- IV Prazosin: A Review of its Pharmacological Properties and Therapeutic Efficacy in Hypertension.- 1. Animal Pharmacodynamic Studies.- 1.1 Mode of Action.- 1.2 Effect on Blood Pressure.- 1.3 Effect on Heart Rate.- 1.4 Effect on Plasma Renin.- 2. Pharmacokinetic Studies in Animals.- 3. Human Pharmacology.- 3.1 Pharmacodynamic Studies.- 3.2 Effect on Renal Function.- 3.3 Effect on Plasma Renin Activity.- 4. Pharmacokinetic Studies in Man.- 4.1 Absorption.- 4.2 Distribution.- 4.3 Elimination.- 4.4 Plasma Concentrations and Clinical Effects.- 4.5 Influence of Disease on Kinetics.- 5. Therapeutic Trials.- 5.1 Prazosin Compared with Placebo.- 5.2 Prazosin Compared with -Methyldopa.- 5.3 Prazosin plus a Thiazide Diuretic Compared with Prazosin Alone.- 5.4 Prazosin Compared with Hydrallazine.- 5.5 Prazosin in Combination with other Antihypertensive Drugs.- 5.6 Prazosin i. …

Taschenbuch. Condición: Neu. This item is printed on demand - Print on Demand Titel. Neuware -Inhaltsangabeof Volume 4.- I Antihypertensive Drugs: Clinical Pharmacology and Therapeutic Use.- 1. Diuretics.- 1.1 Mechanism of Action.- 1.2 Pharmacokinetics.- 1.3 Clinical Use.- 1.4 Side Effects.- 2. Sympathetic Inhibiting Agents.- 2.1 Ganglion Blocking Agents.- 2.2 Guanethidine and Other Adrenergic Neurone Blocking Drugs.- 2.3 Rauwolfia Alkaloids.- 2.4 Methyldopa.- 2.5 Clonidine.- 2.6 Prazosin.- 2.7 -Adrenoceptor Blocking Agents.- 2.8 Labetalol.- 2.9 MAO Inhibitors.- 3. Direct-acting Vasodilators.- 3.1 Hydrallazine.- 3.2 Minoxidil.- 3.3 Diazoxide.- 3.4 Sodium Nitroprusside.- 4. Angiotensin II Analogues and Converting Enzyme Inhibitors.- 5. Treatment Regimens.- 5.1 Mild Hypertension.- 5.2 Moderate to Severe Hypertension.- 5.3 Resistant Hypertension.- 5.4 Hypertensive Emergencies and Presence of Complications.- II Metoprolol: A Review of its Pharmacological Properties and Therapeutic Efficacy in Hypertension.- 1. Animal Pharmacodynamic Studies.- 1.1 -Adrenoceptor Blocking Effect.- 1.2 Partial Agonist Activity.- 1.3 -Adrenoceptor Selectivity.- 1.4 Antihypertensive Effect.- 1.5 Cardiovascular Haemodynamics in Dogs.- 1.6 Toxicology Studies.- 1.7 Dysmotphology and Reproduction Studies.- 2. Animal Pharmacokinetic Studies.- 2.1 Absorption.- 2.2 Half-Life.- 2.3 Distribution.- 2.4 Metabolism.- 3. Human Pharmacodynamic Studies.- 3.1 Effect on Heart Rate and Cardiac Output.- 3.2 Effect on Blood Pressure.- 3.3 -Adrenoceptor Selectivity.- 3.4 Effect on Plasma Renin Activity.- 3.5 Metabolic Effects.- 4. Pharmacokinetic Studies in Man.- 4.1 Absorption.- 4.2 Distribution.- 4.3 Metabolism and Excretion.- 4.4 Plasma Concentration and Clinical Effects.- 5. Therapeutic Trials.- 5.1 Comparison with Placebo.- 5.2 Comparison with Other Drugs.- 5.3 Metoprolol Combined with Other Drugs.- 5.4 Long-term Treatment of Hypertension.- 5.5 Is the Efficacy of Metoprolol in Hypertension Influenced by Frequency of Administration .- 5.6 What is the Role of Metoprolol in Hypertension .- 6. Side Effects.- 7. Contraindications.- 8. Precautions.- 9. Dosage.- 10. Overdosage.- III Labetalol: A Review of its Pharmacology and Therapeutic Use in Hypertension.- 1. Pharmacology.- 1.1 Blockade of - and -Adrenoceptors.- 1.2 Haemodynamic Effects.- 1.3 Effect on Plasma Renin Activity and Plasma Angiotensin II.- 1.4 Effect on Respiratory Function.- 1.5 Animal Toxicological Studies.- 1.6 Mode of Action.- 2. Pharmacokinetics.- 2.1 Absorption.- 2.2 Distribution.- 2.3 Elimination.- 2.4 Plasma Concentration and Clinical Effects.- 2.5 Influence of Disease on Kinetics.- 3. Therapeutic Trials.- 3.1 Open Studies.- 3.2 Placebo-Controlled Trials.- 3.3 Labetalol Compared with a -Adrenoceptor Blocker Alone or in Combination with an -Adrenoceptor Blocker.- 3.4 Use in Phaeochromocytoma.- 3.5 Intravenous Labetalol in Severe Hypertension.- 3.6 Labetalol in Clonidine Withdrawal Hypertension.- 4. What is the Role of Labetalol in Hypertension .- 5. Side Effects.- 6. Precautions.- 7. Dosage.- 7.1 Initial Dosage, Oral.- 7.2 Dosage Adjustment.- 7.3 Intravenous Labetalol.- IV Prazosin: A Review of its Pharmacological Properties and Therapeutic Efficacy in Hypertension.- 1. Animal Pharmacodynamic Studies.- 1.1 Mode of Action.- 1.2 Effect on Blood Pressure.- 1.3 Effect on Heart Rate.- 1.4 Effect on Plasma Renin.- 2. Pharmacokinetic Studies in Animals.- 3. Human Pharmacology.- 3.1 Pharmacodynamic Studies.- 3.2 Effect on Renal Function.- 3.3 Effect on Plasma Renin Activity.- 4. Pharmacokinetic Studies in Man.- 4.1 Absorption.- 4.2 Distribution.- 4.3 Elimination.- 4.4 Plasma Concentrations and Clinical Effects.- 4.5 Influence of Disease on Kinetics.- 5. Therapeutic Trials.- 5.1 Prazosin Compared with Placebo.- 5.2 Prazosin Compared with -Methyldopa.- 5.3 Prazosin plus a Thiazide Diuretic Compared with Prazosin Alone.- 5.4 Prazosin Compared with Hydrallazine.- 5.5 Prazosin in Combination with other Antihypertensive Drugs.- 5.6 Prazosin in Pa. …

Taschenbuch. Condición: Neu. Antihypertensive Drugs Today | R. N. Brogden | Taschenbuch | Cardiovascular Drugs | 175 S. | Englisch | 2012 | Springer | EAN 9789401172707 | Verantwortliche Person für die EU: Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg, juergen[dot]hartmann[at]springer[dot]com | Anbieter: preigu Print on Demand. …